NCT00881400

To Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Fed Conditions

Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Sandoz GmbH and Bristol-Myers Squibb Company (Cefzil) 250 mg/5 ml Cefprozil Oral Suspension Following a 10 ml Dose In Healthy Adults Volunteers Under Fed Conditions

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Sandoz · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

To demonstrate the relative bioavailability of Cefzil 250 mg/5 ml oral suspension fed conditions.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Cefprozil 250 mg/5 ml Oral Suspension (Sandoz, Austria)
DRUG	Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb, USA)

Timeline

• Start date: 2004-06-01
• Primary completion: 2004-06-01
• Completion: 2004-06-01
• First posted: 2009-04-15
• Last updated: 2017-03-29